Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thal...
December 21 2020 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, today announced that Ladenburg Thalmann & Co.
will host a webinar at 3:30p.m. Eastern Time on Tuesday, December
22nd, 2020 highlighting Rett Syndrome and ANAVEX®2-73
(blarcamesine) Phase 2 data as part of Ladenburg Thalmann’s LT
Healthcare Symposia Series.
Speakers include Dr. Jeffrey Neul, Professor of
Pediatrics, Pharmacology, and Special Education, Pediatric
Neurology Director, Vanderbilt Kennedy Center, Nashville, TN and
Dr. Randi Jenssen Hagerman, Distinguished Professor, Department of
Pediatrics, UC Davis MIND Institute, Sacramento, CA. Robert
LeBoyer, Managing Director, Equity Research Ladenburg Thalmann, NY
will be moderating the discussion.
To register for the webinar, please visit
https://zoom.us/webinar/register/9516079699540/WN_nc7LVxdiSA6weZU8SvRmyQ.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73, recently
completed successfully a Phase 2a clinical trials for Alzheimer’s
disease and a Phase 2 proof-of-concept study in Parkinson’s disease
dementia and a Phase 2 study in adult patients with Rett syndrome.
ANAVEX®2-73 is an orally available drug candidate that restores
cellular homeostasis by targeting sigma-1 and muscarinic receptors.
Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer’s disease. ANAVEX®2-73 also
exhibited anticonvulsant, anti-amnesic, neuroprotective and
anti-depressant properties in animal models, indicating its
potential to treat additional CNS disorders, including epilepsy.
The Michael J. Fox Foundation for Parkinson’s Research previously
awarded Anavex a research grant, which fully funded a preclinical
study to develop ANAVEX®2-73 for the treatment of Parkinson’s
disease. ANAVEX®3-71, which targets sigma-1 and muscarinic
receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors:Clint TomlinsonEmail:
ir@anavex.com
Media:Melyssa WeibleElixir
Health Public Relations201-723-5805mweible@elixirhealthpr.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024